Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

AI Briefing

• – Preliminary results of the INVINCIBLE-4 Study show that patients who received INT230-6 prior to standard of care achieved a pathological complete response in 71.4% of cases.
• – The study included 7 patients, 5 of whom achieved pCR, while 2 achieved partial response in the SOC group.
• – These findings suggest a promising therapeutic approach for triple-negative breast cancer patients.